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Abstract 
Objective: Benefit from antidepressant treatment such as selective serotonin reuptake 
inhibitors (SSRIs) may depend on individual differences in acute effects on neural emotion 
processing. The short (‘S’) allele of the serotonin transporter (5-HTT)-linked polymorphic 
region (5-HTTLPR) is associated with both negative emotion processing biases and poorer 
treatment outcomes. Therefore, the aim of the present study was to explore the effects of 5-
HTTLPR on the impact of the SSRI, escitalopram during processing of positive and negative 
emotional images, as well as neutral stimuli. 
Methods: The study employed a double-blind, randomised, placebo-controlled crossover 
design, on 36 healthy Caucasian female participants who underwent fMRI scanning 
following placebo or escitalopram treatment, separated by a 7-day washout period.  
Results: Changes in left amygdala signal with escitalopram treatment during processing of 
emotional stimuli were linearly related to the 5-HTTLPR ‘S’ allele load such that signal to 
positive stimuli decreased and signal to negative stimuli increased with an increasing number 
of low-expressing ‘S’ alleles. While 5-HTTLPR sub-groups were small in size, individual 
subject changes with treatment and task condition increase confidence in findings. 
Conclusions: While preliminary, our findings comprise the first pharmacogenetic study 
demonstrating an effect of the 5-HTTLPR ‘S’ allele load on escitalopram-induced changes in 
amygdala activity during emotional processing, consistent with a 5-HTT expression dosage 
model. The present findings have implications for the impact of this polymorphism on 
antidepressant efficacy in patients with mood and anxiety disorders. 
Keywords: antidepressant, 5-HTTLPR, emotion, serotonin, pharmacogenetics, fMRI  
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Introduction 
Variability in therapeutic antidepressant treatment response is high, with 50% to 70% 
of patients not responding to first-line antidepressant treatment (Kemp et al., 2008; Trivedi, 
2006). Given that acute antidepressant action lays the foundation for downstream changes 
(Belmaker and Agam, 2008) and therapeutic outcomes (Harmer et al., 2009; Pringle et al., 
2011; Roiser et al., 2012), advancements in the understanding of the variation in acute 
antidepressant treatment responses may provide important leads towards personalised 
medicine for affective disorders (Hariri et al., 2002; Munafò et al., 2008; Murphy et al., 2012; 
Outhred et al., 2012). Here, we examine potential pharmacogenetic mechanisms that may 
impact on acute selective serotonin reuptake inhibitor (SSRI) treatment effects on neural 
changes that occur during processing of emotional stimuli; these early changes are important 
because they may underpin treatment response (Harmer et al., 2009; Pringle et al., 2011; 
Roiser et al., 2012). The serotonin transporter protein (5-HTT) is the initial and key target of 
the commonly prescribed (Stephenson et al., 2013)  SSRIs (Klein et al., 2006). 5-HTT is 
encoded by the gene SLC6A4, the expression of which is modulated by a polymorphism in 
the promoter region, termed 5-HTTLPR (Del-Ben et al., 2005; Heils et al., 1996; Lesch et al., 
1996). The short (‘S’) allele of the 5-HTTLPR is associated with lower transcriptional 
efficiency of 5-HTT compared with the long (‘L’) allele, leading to dysfunctional regulation 
within 5-HT system (Canli and Lesch, 2007; Heils et al., 1996; Lesch et al., 1996; Lesch and 
Gutknecht, 2005; Smeraldi et al., 1998). Previous studies on large samples and meta-analyses 
have shown that, in comparison to ‘L’ allele carriers, ‘S/S’ homozygotes display lower 
remission and response rates when treated with SSRIs (see Huezo-Diaz et al., 2009; Kato and 
Serretti, 2010; Licinio and Wong, 2011; Serretti et al., 2007). As single-dose SSRI treatment 
modulates neural activity consistent with an improvement in emotion processing bias (Kemp 
et al., 2004a; Outhred et al., 2013, in press), variability in this effect could be explained, in 
part, by variation in 5-HTT levels due to 5-HTTLPR allelic variation. For the first time, we 
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integrate and draw upon the imaging genetics (see Hariri et al., 2006) and imaging 
pharmacology (see Honey and Bullmore, 2004) paradigms to determine the impact of 5-
HTTLPR on our previously reported (Kemp et al., 2004a; Outhred et al., in press) acute 
effects of 5-HTT blockade by the SSRI, escitalopram, on emotion processing. In doing so, the 
present study will be the first to examine the pharmacogenetics of antidepressant-induced 
modulation of emotion processing. 
The pharmacogenetics of SSRI treatment is firstly examined within the context of 5-
HTT pharmacology. SSRIs bind directly to 5-HTT inhibiting reuptake of serotonin (5-HT) 
(Roseboom and Kalin, 2011; Zahajszky et al., 2011). A single 20 mg dose of escitalopram, 
for example, produces an average of 75% ± 5% 5-HTT blockade at maximum concentration 
(Klein et al., 2006). Though specific mechanisms remain to be demonstrated, it is known that 
‘S’ carriers have chronic dysregulation of 5-HT (Hariri et al., 2005; Risch et al., 2009) and 
SSRI treatment at the acute stage leads to further dysregulation, reducing 5-HT availability in 
the synapse (Ruhé et al., 2009). With half the 5-HT reuptake with the ‘S’ allele (Lesch et al., 
1996), maintenance of 5-HT pools in presynaptic neurons for subsequent release may be 
decreased, which may increase 5-HT1A autoreceptor sensitivity (Smeraldi et al., 1998) 
leading to decreased 5-HT availability in the synapse (Canli and Lesch, 2007; Lesch and 
Gutknecht, 2005). The acute action of SSRIs in ‘S’ carriers may further decrease 5-HT 
availability in the synapse through a mechanism of increased negative feedback from 
increased 5-HT1A autoreceptor sensitivity when 5-HT remains in the synapse after release 
under 5-HTT blockade (Celada et al., 2013). An alternative is that the low 5-HT pools in ‘S’ 
carriers become more exhausted with decreased reuptake with SSRI blockade, leading to 
further decreases in 5-HT availability in the synapse (Ruhé et al., 2009). Regardless, 
increasing 5-HTT occupancy with SSRIs in ‘S’ carriers is associated with worsening 
treatment outcome due to increased tonic 5-HT dysregulation (Ruhé et al., 2009). 
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The greatest density of 5-HTT across the brain are found in regions including the mid 
brain raphe nuclei and the amygdala (Ruhé et al., 2009) and are targets for 5-HTT blockade 
with SSRIs (Harsing, 2006; Lanzenberger et al., 2012; Meyer et al., 2004). The amygdala is a 
terminal projection of the raphe nuclei: and increase in the firing rate of 5-HTergic cells in 
the raphe nucleus, causes an increase in extracellular 5-HT levels in the amygdala (Crespi, 
2009). 5-HTT blockade with SSRI treatment results in an increase in extracellular 5-HT in 
amygdala through a relative increase in extracellular 5-HT from the raphe projections 
compared with that of the amygdala, which may subsequently lead to positive changes with 
treatment (Licht et al., 2010). Though single doses of SSRIs have been shown to modulate 
prefrontal cortex (PFC; including, dorsolateral PFC and inferior frontal gryus) and amygdala 
activity, consistent with a decrease in negative emotional bias (Outhred et al., 2013, in press; 
see also Kemp et al., 2004a), the effects of 5-HTTLPR variation on the pharmacodynamic 
effects of SSRIs are expected to be greater in the amygdala compared to PFC regions because 
5-HTT density is low in the PFC (Ichise et al., 2003; Kobiella et al., 2011; Mann et al., 2000). 
Indeed, 5-HTTLPR is not related to 5-HTT density at the PFC (Mann et al., 2000) but is 
related to density in the amygdala (Kobiella et al., 2011; Reimold et al., 2007). Therefore, 
regulation of extracellular 5-HT levels at the amygdala with 5-HTT expression—as 
modulated by 5-HTTLPR—may mediate the impact of SSRIs on amygdala functioning. 
In accordance with current models of antidepressant action (Roiser et al., 2012), the 
amygdala is a region that may differentially respond to an acute dose of an SSRI depending 
on expression levels of 5-HTT, as influenced by 5-HTTLPR. The amygdala is involved in 
emotion processing, responding to the salience of stimuli (Luo et al., 2010; Pourtois et al., 
2010), and modulations in amygdala response are shown with single dose SSRI treatment 
(Klein et al., 2006; Murphy et al., 2009; Outhred et al., 2013, in press). These acute changes 
are associated with decreases in negative emotional biases, which are common features of 
affective disorders including major depressive disorder and generalised anxiety disorder 
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(Harmer et al., 2009; Outhred et al., 2013, in press; Pringle et al., 2011; Roiser et al., 2012). 
These early neural changes are thought to lay the foundation for improvement in symptoms 
(Harmer et al., 2009; Murphy et al., 2009; Roiser et al., 2012), leading to downstream 
changes (see Belmaker and Agam, 2008), that coincide with the typical four-to-six week 
timeframe. Though there is both converging (see Tranter et al., 2009) and diverging (see 
Douglas et al., 2011) cognitive evidence for this proposal, the relationship between early 
neural changes and later improvement in symptoms remains to be directly determined. In 
terms of single dose SSRI administration effects, the decreases in amygdala reactivity to 
negative emotional stimuli (Anderson et al., 2007; Del-Ben et al., 2005; Heils et al., 1996; 
Lesch et al., 1996; Murphy et al., 2009) and increases in amygdala to positive emotional 
stimuli (Outhred et al., 2013, in press) may be linked to increases in extracellular 5-HT levels 
with 5-HTT blockade in treatment responders (Lanzenberger et al., 2012). Therefore, 
pharmacogenetics of single dose SSRI treatment may be characterised—at least in part—by 
5-HTT expression-related modulation of amygdala responses to positive and negative stimuli 
with SSRI 5-HTT blockade. However, the mechanism underpinning impact of the 5-
HTTLPR on SSRI 5-HTT blockade, subsequent changes in amygdala activity during emotion 
processing is yet to be illustrated. This is the goal of the present study. 
The low 5-HTT expressing ‘S’ variant of 5-HTTLPR has been related to increased 
amygdala activity during salient, emotional stimuli (Hariri et al., 2002; Munafò et al., 2008; 
Murphy et al., 2012; Outhred et al., 2012). These findings, along with concordant personality 
(Lesch et al., 1996), cognitive neuropsychological findings (Canli and Lesch, 2007), and 
clinical outcomes (Caspi et al., 2003; Li and He, 2007), have led to the notion that ‘S’ allele 
carriers have increased negative emotion biases through relative hyper-reactivity of the 
amygdala to negative emotional stimuli (Canli and Lesch, 2007; Hariri and Holmes, 2006; 
Outhred et al., 2012). Taken together, this background suggests that the influence of 5-
HTTLPR on changes in emotion biases under acute SSRI treatment may increase amygdala 
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activation in those with the low expression ‘S’ allele during processing of negative emotion 
stimuli By contrast, there may be an increase in amygdala activation in those with the high 
expression ‘L’ allele with treatment during processing of positive emotion stimuli. Given that 
the 5-HTTLPR ‘S’ variant is associated with negative bias across positive and negative 
stimuli, as well as neutral stimuli (Heinz et al., 2007), we sought to the explore the impact of 
5-HTTLPR on our previously established effects (Outhred et al., in press) of acute SSRI 
treatment across valence categories on left (L) amygdala activity . Previous research (e.g., 
Caspi et al., 2003; Freidlin et al., 2002; Hariri et al., 2005; Risch et al., 2009) has 
characterised 5-HTTLPR allele loading whereby more ‘L’ alleles results in more 5-HTT 
expression in a dose-response manner. Hence, the present study examines  response to a 
single dose SSRI probe in participants with characterised by differentially functioning 5-
HTergic systems according to the 5-HTTLPR polymorphism. 
Here we explore the impact of 5-HTTLPR on the left amygdala responses to highly 
arousing positive and negative images as well as low-arousal neutral images in healthy 
participants after acute 5-HTT blockade with escitalopram (20 mg,. Consistent with our 
previous research (Outhred et al., 2013, in press) and 5-HTT literature showing that ‘L’ 
carriers have better treatment outcomes than ‘S’ carriers both at the cellular and behavioural 
level, we predicted linear relationships between 5-HTTLPR and left amygdala BOLD 
responses during processing of images after single dose escitalopram relative to placebo. 
Specifically, we hypothesised that with escitalopram treatment, the number of ‘L’ alleles 
would be associated with a: (1) greater increase in left amygdala to positive images with 
escitalopram treatment and, (2) greater decrease in left amygdala to negative images. In line 
with our previous findings (Outhred et al., in press) and the literature concerning 5-HTTLPR 
and amygdala response to neutral stimuli (e.g., Heinz et al., 2007), we also hypothesised that 
(3) more ‘L’ alleles would be associated with a greater increase in left amygdala to neutral 
images with escitalopram treatment, similar to that hypothesised for positive images. 
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Methods 
Participants 
Thirty-six right-handed, healthy Caucasian, female participants (mean age = 25.08; 
SD = 6.49) were recruited and completed the trial, as previously described (see Outhred et al., 
in press). All participants provided informed consent in accordance with the Australian 
National Health and Medical Research Council (NHMRC) guidelines and in accordance with 
the Declaration of Helsinki. The Sydney University Human Research Ethics Committee 
(13901) and the Northern Sydney Central Coast Area Health Service Human Research Ethics 
Committee (1105-178M) granted ethical approval. Our trial was then registered with the 
Australian New Zealand Clinical Trials Registry (ANZCTR; ACTRN12611000719932). 
From telephone screening, potential participants were determined to be free from medication 
(other than hormonal contraceptives), physical and psychiatric illness, major depressive 
disorder (PHQ-9 assessment; Kroenke et al., 2001) or generalised anxiety disorder symptoms 
(GAD-7 assessment; Spitzer et al., 2006). Additionally, participants had no history of 
previous psychiatric illness or psychiatric medication use. Participants were free from illicit 
drug use, alcoholism, smoking, brain injury, neurological disorders, loss of consciousness for 
longer than five minutes, and contraindications for fMRI scanning. Finally, participants 
abstained from caffeine on the morning of the experiment and no participant tested positive 
on pregnancy tests that were conducted at each session. See Table 1 for participant 
characteristics according to 5-HTTLPR grouping; no group differences were observed. 
Genotyping 
DNA was extracted from saliva samples and genotypes were then determined for the 
5-HTTLPR and rs25531 polymorphisms (Dannlowski et al., 2007; Hu et al., 2005; Kato et 
al., 2013). The ‘Lg’ variant of rs25531 and the ‘S’ 5-HTTLPR allele are similar in function; 
thus, the ‘Lg’ variant is categorised similarly (Hu et al., 2005). 5-HTTLPR and rs25531 were 
determined according to protocols described previously (see Bryant et al., 2010; Quinn et al., 
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2012). Genotypes were scored independently by two researchers. The functional 5-HTTLPR 
genotypes (taking into account rs25531) were categorised as ‘S/S’ (n = 8; 22%), ‘S/L’ (n = 
21; 58%), and ‘L/L’ (n = 7; 29%), and were found to be in Hardy-Weinberg equilibrium, χ2 
(1) = 1.011, p = 0.315. See the Supplement for separate 5-HTTLPR and rs25531 grouping 
number breakdowns. 
Experimental and Emotion Processing Task design 
All participants were tested under placebo (saccharin) and escitalopram (20 mg; per 
os) conditions using a randomised, double-blind, placebo controlled, cross-over design, with 
a washout period of one week (or five half-lives [t1/2 = 26.7 hours]; Sogaard et al., 2005). An 
equal number of participants had either escitalopram or placebo in their first testing session. 
Functional magnetic resonance imaging (fMRI) during an emotion processing task was 
conducted 4 hours post-treatment to coincide with expected peak pharmacokinetic effects of 
escitalopram (mean max = 4.0 hours, Alphapharm, 2012; tmax = 3.0 ± 1.5 hours, Sogaard et 
al., 2005). As previously described (see Outhred et al., in press), a block design, emotion 
processing task was constructed: three blocks contained high-arousal positive images, three 
blocks contained negative valance images, three blocks contained low-arousal, neutral 
valance images, and nine blocks contained fixation crosses (see Supplement for further 
details). Stimuli were selected from the International Affective Picture System (Lang et al., 
2008) in order to elicit complex emotion processing (Lang et al., 1993). The blocks of 
fixation crosses were followed by each IAPS image block. Each of the blocks comprised of 
five images that were presented for four seconds each. During all trials, images were unique 
within and across sessions and participants were randomised to either of two forms of the 
task in their first session. Blocks of images were randomised within each form. A number of 
hormonal, behavioural, and neurophysiological manipulation checks were performed (see 
Supplement). These manipulation checks included assessing the impact of potential 
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unblinding of treatment due to the subjective occurrence of side effects on the results of the 
study. The assessments showed no impact on the results (see Supplement). 
fMRI data acquisition 
Imaging was performed at Advanced Research and Clinical Highfield Imaging, 
University of Sydney, Royal North Shore Hospital (ARCHI; a dedicated research facility) 
using a 3.0 T Siemens Trio scanner, as previous described (see Outhred et al., in press). 
Thirty-six consecutive axial slices (4 mm thickness) parallel to the anterior–posterior 
commissure covering the whole brain were imaged using a T2*-weighted gradient echo EPI 
sequence (echo time [TE] = 32 ms; repetition time [TR] = 2000 ms; matrix = 64 × 64; flip 
angle = 90°). The field of view was 240 mm and the effective in plane functional spatial 
resolution was 3.75 mm. For each functional run, 360 volumes were collected after 
discarding the first six. For anatomical reference, high-resolution, whole-brain images were 
also acquired: TR = 1570 msec; TE = 3.22 msec; flip angle = 15°; matrix 512 × 512 × 192 
mm. Participant movement was minimised by securing the head within the coil using 
padding. 
fMRI data analysis 
Here we differentiate between (a) analyses performed and reported in our previous 
study (see Outhred et al., in press) that were designed to extract contrast percent signal 
change (PSC) values from the left amygdala to determine the experimental, within-subjects 
treatment and task effects and (b) analyses performed for the present study that were designed 
to determine the between-subjects effects of 5-HTTLPR allele loading on the effect of 
treatment on the task conditions using the previously determined PSC values from the left 
amygdala. 
For our previous study, the imaging data was pre-processed and analysed using the 
image processing routines implemented within the statistical parametric mapping software 
package, SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/; Wellcome Trust Centre 
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for Neuroimaging). Images for each subject were first corrected for susceptibility-by-
movement artifacts and then realigned to the first volume of the time series. Realigned 
images were spatially normalised into a standard stereotactic space (Montreal Neurologic 
Institute template) and smoothed with a Gaussian kernel (FWHM 8 mm) in order to minimise 
anatomical differences. The BOLD response at each voxel was modelled with a canonical 
hemodynamic response function and its temporal derivative. Brain activation contrast images 
were determined from the positive, negative, and neutral images contrasted against fixation 
images, at each treatment session for each participant in order to determine the effects of 
treatment on emotion processing. These individual contrast images were then used in the 
second-level random effects model in order to determine regional responses for the whole 
sample. We conducted a whole-brain analysis in order to ensure the emotion processing task 
and treatments activated regions associated with affective processing, and critically, our 
region of interest (ROI) for the present study, the left amygdala (as previously defined; 
Maldjian et al., 2003; Tzourio-Mazoyer et al., 2002) was activated. In order to determine the 
interaction effect of treatment (escitalopram, placebo) × valence (positive, negative, neutral), 
an analysis of variance (ANOVA) on the valance > fixation contrasts were performed for the 
ROIs. This analysis was then followed up with dependent samples t-tests in order to 
determine the direction of the effects. For the whole brain analysis, we employed an alpha 
threshold of p < 0.05 (family-wise error corrected; FWE-corrected). For all a priori ROI 
analyses, we employed an alpha threshold of p < 0.05 (small volume, uncorrected) and a 
spatial extent of 20 or more voxels per cluster for a principled approach in controlling for 
false positives (Bennett et al., 2009; Poldrack et al., 2008). For reference, results tables of the 
whole brain analysis and ROI analyses of the treatment and stimulus condition effects are 
provided in Supplement Tables S1, S2, and S3, and are reported and discussed in detail in our 
previous work (see Outhred et al., in press). For each participant at each session, percent 
signal change (PSC) for each of the positive, negative and neutral images were estimated 
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using MarsBaR (Brett et al., 2002). The ROI for PSC analysis were determined from the 
significant left amygdala cluster at the second-level analysis. This analysis was conducted to 
determine the effect of treatment on emotion processing. 
For the present study, the left amygdala PSC values from each participants’ task 
conditions (positive, negative, neutral) at the escitalopram session were subtracted from those 
of the placebo session. The resultant PSC values for each task condition represented the 
within subjects relative change in left amygdala activity with escitalopram treatment, with 
positive PSC values representing increased activity with treatment relative to placebo. 
Consistent with a dosage (or dose-response) model of 5-HTT expression (Caspi et al., 2003; 
Freidlin et al., 2002), linear regression is a common data analysis strategy (Hariri et al., 2005; 
Risch et al., 2009). Consequently, linear regressions were performed in IBM SPSS 20 for 
OSX with 5-HTTLPR allele loading (‘S/S’ = – 1; ‘S/L’ = 0; ‘L/L’ = 1) as the predictor and 
the left amygdala PSC values of each task condition (positive, negative, neutral); these 
analyses provided tests for Hypotheses 1 and 2, and 3, respectively (as above). For 
verification purposes, the linear regression analyses were supported on a background of a 
significant repeated-measures analysis of variance (ANOVA) testing for a 5-HTTLPR × 
Treatment × Task Condition interaction, F(2, 33) = 3.344, p = .048, partial η2 = .169. In order 
to illustrate that the regression models are consistent with the aforementioned 5-HTT 
expression dose-response model, Cook’s Distances (Cook and Weisberg, 1982) were 
calculated for each data point and employed in the following steps. First, the Cook’s Distance 
values were checked for values greater than one, which would indicate data points that have a 
specific influence on (or drove the significance of) the determined regression slopes. Second, 
in order to determine whether any 5-HTTLPR group had a specific influence on—or had a 
significantly greater loading, thereby driving significance of—the determined regression 
slopes, one-way ANOVAs were performed on the Cook’s Distance values from each 
regression slope and checked for significant differences between 5-HTTLPR groups. 
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Results 
fMRI results: 5-HTTLPR on Left Amygdala responses to High-Arousal Positive and 
Negative Images with Escitalopram 
  The linear regression on the PSC values on positive images with 5-HTTLPR 
grouping as the predictor was significant, r2 = .155, adjusted r2 = .131, F(1, 34) = 6.255, p = 
.017. The direction of the prediction supported our hypothesis, such that with more ‘L’ 
alleles, there was a greater increase in left amygdala during positive images with escitalopram 
treatment.  
The linear regression on the PSC values on negative images with 5-HTTLPR 
grouping as the predictor was significant, r2 = .156, adjusted r2 = .131, F(1, 34) = 6.275, p = 
.017. Again, the direction of the prediction supported our hypothesis, such that with more ‘L’ 
alleles, there was a greater decrease in left amygdala during negative images with 
escitalopram treatment. See Figure 1 for a visualisation of these results. 
No 5-HTTLPR group was specifically influential on the determined positive image 
regression slope (F[2, 33] = 1.395, p = .262) or the negative image regression slope (F[2, 33] 
= 0.589, p = .561). Additionally, no data point was significantly influential (all Cook’s 
Distances < 1). 
fMRI results: 5-HTTLPR on Left Amygdala responses to Low-arousal Neutral Images 
with Escitalopram 
The linear regression on the PSC values on neutral images with 5-HTTLPR grouping 
as the predictor was also significant, r2 = .236, adjusted r2 = .213, F(1, 34) = 10.486, p = .003. 
The direction of the prediction was consistent with our hypothesis, and parallel to the positive 
images, such that with more ‘L’ alleles, there was a greater increase in left amygdala activity 
during neutral images with escitalopram treatment. 
Again, no data point (all Cook’s Distances < 1) or 5-HTTLPR group was specifically 
influential on the determined neutral image regression slope (F[2, 33] = 0.659, p = .524). 
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Discussion 
The present study examined the impact of 5-HTTLPR on amygdala responses to 
highly arousing positive and negative images as well as low-arousal, neutral images in 
healthy participants after acute 5-HTT blockade by a single dose of escitalopram (20 mg). 
Consistent with predictions, 5-HTTLPR allelic variation predicted amygdala modulation of 
positive and negative stimuli by the SSRI, escitalopram. Specifically, with more ‘L’ alleles, 
amygdala responses during positive stimuli increased while responses to negative stimuli 
decreased under the escitalopram condition. Additionally, amygdala responses increased 
during neutral stimuli with more ‘L’ alleles, paralleling the effect observed for positive 
stimuli. These findings suggest for the first time, that the 5-HTTLPR polymorphism can 
influence the acute effects of an SSRI such as escitalopram, on brain response to emotional 
cues that may underlie changes in emotional bias. 
Building on our earlier pharmaco-fMRI findings (Outhred et al., 2013, in press), the 
present pharmacogenetic-fMRI study found that ‘L’ alleles potentiated brain response to 
positive emotional cues while attenuating response to negative cues following enhancement 
of synaptic serotonin with escitalopram. This was demonstrated by an increase in amygdala 
activation (which may reflect increased salience; Luo et al., 2010; Pourtois et al., 2010) 
during positive images, and a decrease in amygdala activation (decreased salience) during 
negative images. With respect to neutral images, escitalopram increased amygdala (increased 
salience) with more ‘L’ alleles, in a similar manner to that observed during the processing of 
positive images. Consistent with dose-response models of 5-HTT expression (Caspi et al., 
2003; Freidlin et al., 2002; Hariri et al., 2005; Risch et al., 2009), no single 5-HTTLPR group 
(or single participant, for that matter) specifically influenced the determined linear 
relationship between 5-HTTLPR and the neural changes that were observed with 
escitalopram treatment. These observations suggest that, in those with more ‘L’ alleles, a 
single dose of a commonly prescribed SSRI (Stephenson et al., 2013) facilitates a more 
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positive bias toward emotional and neutral stimuli within the emotion circuitry, consistent 
with cognitive neuropsychological models of antidepressant action (Harmer et al., 2009; 
Outhred et al., 2013, in press; Pringle et al., 2011; Roiser et al., 2012). Acute improvement in 
cognitive neuropsychological processes with antidepressant treatment may form the basis for 
downstream changes and symptom amelioration with therapeutic administration (Harmer et 
al., 2009; Outhred et al., 2013, in press; Pringle et al., 2011; Roiser et al., 2012). The present 
findings suggest greater improvement in these processes in carriers of more ‘L’ alleles; thus 
providing a potential explanation for the manner in which the ‘L’ alleles is able to predict 
improved response to and remission with antidepressant treatment (Kato and Serretti, 2010; 
Licinio and Wong, 2011; Ruhé et al., 2009; Serretti et al., 2007). Future research should 
examine whether the differential acute effects of antidepressants on positive, negative, and 
neutral stimuli associated with 5-HTTLPR variation are predictive of longitudinal therapeutic 
changes with chronic treatment in patients with affective disorders. Given that 5-HTT is a 
target of antidepressants at which initial changes occur, 5-HTTLPR is a likely candidate for 
explaining variation with treatment. However, it is unlikely that 5-HTTLPR alone underpins 
the downstream changes occurring with chronic, therapeutic administration. Other candidate 
genes that may regulate downstream cellular changes and cognitive neuropsychological 
effects include those involved in the expression of neurotropic factors such as brain derived 
neurotropic factor (BDNF) Val66Met (Chen et al., 2011; also see Gatt et at., 2009; Quinn et 
al., 2012). Given pharmacogenetic testing for antidepressant treatment has potential clinical 
utility (initially with respect to metabolism and dosage; e.g., Dinama et al., 2014), the present 
study provides impetus to further investigate the pharmacogenetics of acute and downstream 
cellular and cognitive neuropsychological changes associated with treatment response and 
outcome. 
Based on the present study’s findings within the context of the aforementioned 
literature, a framework was developed for understanding the potential impact of 5-HTTLPR 
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on acute SSRI administration on differential change in emotional biases, having 
consequences for downstream changes and symptom amelioration (see Figure 2). Building on 
previous models (Harmer et al., 2009; Outhred et al., 2013, in press; Pringle et al., 2011; 
Roiser et al., 2012), a potential superordinate mechanism is proposed as follows. 5-HTT 
expression plays a role in the manner in which increases in 5-HT with SSRI 5-HTT blockade 
are regulated (Ruhé et al., 2009). Decreased 5-HT levels in ‘S’ carriers with acute SSRI 
treatment in contrast to increased 5-HT levels in ‘L’ carriers are hypothesised to be related to 
differential 5-HT1A autoreceptor sensitivity or 5-HT pooling, or both (Ruhé et al., 2009). 
Regardless, individuals with low expressing ‘S’ allele have increased tonic dysregulation of 
5-HT following acute administration of treatment, underpinning increased amygdala activity 
consistent with an increase in negativity biases. In contrast, those with the high expressing 
‘L’ allele have increased tonic regulation of 5-HT with treatment, leading to an increase in 
biases towards positive emotion. With increases in 5-HT, PFC (such as the dorsolateral PFC 
and inferior frontal gyrus) activity is modulated consistent with changes in emotion bias; 
however, 5-HTT expression is low in this region and thus PFC modulation with treatment 
may not be directly influenced by 5-HTTLPR variation (as shown in white boxes). This 
aforementioned superordinate mechanism may account for variation in downstream changes, 
symptom amelioration, and thus therapeutic treatment responses by 5-HTTLPR variation. In 
addition to providing important leads towards illustrating the neural mechanisms of 
antidepressant action, the present study may have implications for future research converging 
on the known associations between 5-HTTLPR and suicidality (Lanzenberger et al., 2012; Li 
and He, 2007) and the effects of acute treatment on suicidality (Gibbons et al., 2012; Kemp et 
al., 2013; Licht et al., 2010). It could be predicted that the increased negativity bias with more 
‘S’ alleles under acute antidepressant treatment may be related to differential treatment 
responses in suicidality: either increased suicidality (Licht et al., 2010) or no treatment effect 
on suicidality (Gibbons et al., 2012), consistent with the two major perspectives, respectively. 
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Limitations 
A potential limitation of the present study was the small numbers of participants in the 
homozygote ‘S/S’ and ‘L/L’ 5-HTTLPR groupings. However, the within-subjects nature of 
the experiment—with both treatment and task conditions—and observing within-subject 
changes at the individual subject level increases our confidence in the findings reported here. 
Another possible limitation of the present study was that a female-only sample was 
employed. As sex differences in neurophysiological responses to affective stimuli (Kemp et 
al., 2004b; Kret and De Gelder, 2012) and effects of ovarian steroids—and variation thereof 
within the menstrual cycle—on serotonergic pathways (see Bethea et al., 2002) have been 
reported, the present study’s findings may not be generalizable to the male population. 
Therefore, it is imperative to extend the present study’s findings to males in future studies as 
emotion and drug effects may differ. Nevertheless, the within-subjects design and extensive 
manipulation checks (see Supplement), along with the employment of a homogenous, well-
characterised sample, again serve to increase our confidence in the observed findings. 
Summary 
We demonstrate for the first time a pharmacogenetic effect within the brain emotion 
circuitry by variation in 5-HTTLPR, which affects brain responses to emotional cues 
following a single dose of the commonly prescribed SSRI, escitalopram. Drawing upon 
findings that the initial target of SSRIs is the 5-HTT and that 5-HTT expression is associated 
with 5-HTTLPR, the present study found that variation in acute neural changes with SSRI 
treatment is partially explained by 5-HTTLPR. Specifically, the ‘S’ allele was related to 
amygdala activity consistent with an increasing negative emotion processing bias and the ‘L’ 
allele related to amygdala activity consistent with increasing positive emotion processing bias 
following a single dose of escitalopram. Therefore, we observed differential responding to an 
SSRI during presentation of emotional stimuli that was dependent on levels of 5-HTT 
expression. A framework for understanding the pharmacogenetics of acute SSRI treatment 
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was proposed and this needs to be further examined in clinical samples. With the support of 
these preliminary findings, future research in the pharmacogenetics of antidepressant 
treatment at acute and chronic stages with larger clinical samples will provide important leads 
towards personalised medicine in affective disorders. 
Supplementary material is available at the Australian and New Zealand Journal of 
Psychiatry's website <url>. 
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Table 1 
Participant demographics by 5-HTTLPR 
 
5-HTTLPR 
 
 ‘S/S’  
(n = 8) 
 ‘S/L’  
(n = 21) 
 ‘L/L’  
(n = 7) 
Group 
Differences 
Age  
(years; SD) 
22.50 
(3.67) 
 
24.95 
(6.32) 
 
28.43 
(8.66) 
F(2, 33) = 1.623 
p = .213 
Education  
(years; SD) 
16.88 
(3.14) 
 
16.95 
(2.67) 
 
18.14 
(3.02) 
F(2, 33) = 0.514 
p = .603 
BMI  
(kg/m2; SD) 
21.79 
(2.54) 
 
22.88 
(3.17) 
 
21.64 
(2.30) 
F(2, 33) = 0.708 
p = .500 
PHQ-9  
(SD) 
1.75 
(1.04) 
 
1.48 
(1.21) 
 
1.00 
(1.00) 
F(2, 33) = 0.830 
p = .445 
GAD-7  
(SD) 
1.00 
(1.15) 
 
1.10 
(1.14) 
 
1.14 
(0.90) 
F(2, 33) = 0.029 
p = .971 
       
Note. SD = standard deviation; BMI = body mass index; PHQ-9 = Patient Health 
Questionnaire; GAD-7 = Generalised Anxiety Disorder questionnaire.   
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Figure 1. The impact of 5-HTTLPR on left amygdala percent signal change with 
escitalopram treatment for positive and negative stimuli. Panel A. The left amygdala region 
of interest for percent signal change extraction (the only region of interest for the present 
study). Panel B. The positive relationship between ‘L’ alleles and signal change of the left 
amygdala during positive images with escitalopram. Panel C. The negative relationship 
between ‘L’ alleles and signal change of the left amygdala during negative images with 
escitalopram. 
 
Figure 1 is attached separately.
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Figure 2. A preliminary framework for understanding the impact of 5-HTTLPR on acute 
SSRI administration leading to differential change in emotional biases, leading to 
downstream changes and symptom amelioration. 5-HTT expression plays a role in the 
manner in which increases in 5-HT with SSRI 5-HTT blockade are regulated. Individuals 
with low expressing ‘S’ allele have increased tonic dysregulation of 5-HT with treatment 
leading to amygdala (AMY) activity modulation consistent with an increased negative 
emotion bias. In contrast, those with the high expressing ‘L’ allele have increased tonic 
regulation of 5-HT with treatment, leading to modulation consistent with an increased 
positive emotion bias. With increases in 5-HT, PFC (such as dorsolateral PFC and inferior 
frontal gyrus) activity is modulated consistent with changes in emotion bias (Outhred et al., 
2013, in press); however, 5-HTT expression is low in this region and thus PFC modulation 
with treatment may not be directly influenced by 5-HTTLPR variation (as shown in white 
boxes).  
 
Figure 2 is also attached separately 
